Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk. Looking at options history for Novo Nordisk (NYSE:NVO) we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 62% with bearish. From the overall spotted trades, 3 are puts, for a total amount of $155,555 and 5, calls, for a total amount of $255,360. What's The Price Target? Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $175.0 for Novo Nordisk during the past quarter. Analyzing Volume & Open Interest Assessing

The National Health Service (NHS) has prescribed Novo Nordisk A/S’s (NYSE:NVO) weight-loss drug Wegovy far less often than anticipated, struggling with a shortage of weight management clinics required to distribute the popular treatment. Since its launch, the drug has been prescribed just 3,300 times, significantly below the 13,500 patients expected to receive it in its first year, according to a Financial Times analysis of NHS England data. Demand for Wegovy is set to increase following the Medicines and Healthcare Products Regulatory Agency’s (MHRA) approval for its use in reducing the risk of serious heart problems or strokes in overweight and obese adults. Despite this, the drug

In Wednesday’s pre-market trading, shares of Novo Nordisk A/S (NYSE:NVO) are witnessing a fall after the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) approved a new indication for Novo Nordisk’s semaglutide, Wegovy, to reduce the risk of heart complications or strokes in overweight and obese adults, What Happened: At the time of writing, Novo Nordisk was trading 1.25% lower at $131.61 in the pre-market after closing at $133.28 on Tuesday, according to Benzinga Pro. The weak pre-market performance can also be linked to increased competition in the weight loss drugs market. Last week, shares of Novo Nordisk and rival Eli Lilly (NYSE:LLY) dipped after Pfizer Inc. (NY

Embecta Corp (NASDAQ:EMBC), a manufacturer of disposable insulin pen needles and syringes, is considering a potential sale following a significant drop in its share price since being spun off from health tech giant Becton, Dickinson and Company (NYSE:BDX). The medical technology company, which supplies approximately 8 billion syringes and needle pens annually across more than 100 countries, has engaged advisers from Centerview Partners to explore a sale. Embecta’s share price has plummeted nearly 70% since its April 2022 spin-off, leaving the Nasdaq-listed firm valued at $2.1 billion. The decline is attributed to several factors, including the impact of GLP-1 drugs such as Novo Nord

On Tuesday, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) approved a new indication for Novo Nordisk A/S’s (NYSE:NVO) semaglutide (Wegovy) to reduce the risk of overweight and obese adults suffering heart problems or strokes. This medicine, a GLP-1 receptor agonist, was already approved for use in the treatment of obesity and weight management, alongside diet, physical activity, and behavioral support. Also Read Oral Weight Loss Drugs Vs. Injections – Pills Are Promising Yet Challenging Frontier. The approval means that semaglutide is the first weight loss drug to be prescribed to prevent cardiovascular events, such as cardiovascular death, non-fatal heart at

- Bloomberg

Hims & Hers Health Inc. (NYSE:HIMS) shares are moving higher on Monday after the company appointed former Novo Nordisk COO and President Kåre Schultz‘s to its Board of Directors. Schultz brings extensive experience from his leadership roles at Novo Nordisk Inc.  (NYSE:NVO), Teva Pharmaceutical Industries LTD (NYSE:TEVA) and Lundbeck. At Novo Nordisk, Schultz was instrumental in establishing the company as a leader in diabetes care. “Kåre’s experience gives us an incredible wealth of expertise as we bring together the most valuable elements of clinical excellence, healthcare and technology to redefine health and wellness for our customers.” said CEO Andrew Dudum. Price Action: H

President Joe Biden‘s decision on Sunday to drop his bid for a second term in the White House was “yet another curveball for equity investors,” according to RBC Capital Markets analyst Lori Calvasina. So far this year, investors have exhibited “the same amount of discomfort in talking about the US election and its stock market/economic implications in our meetings that one might feel by staring at the sun for too long,” Calvasina wrote in a Monday analyst note. How the stock market will react to Biden’s historic decision “remains to be seen,” she adds. “The main thing we've been remembering,” Calvasina says, “is how so many of the US-based investors we've spoken with this year seeme

The race to develop oral weight loss medications is intensifying as companies like Roche Holdings AG (OTC:RHHBY), Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) strive to create alternatives to injectable drugs. While these pills offer a promising solution in the fight against obesity, experts caution that they may not wholly replace injectable options. Clinical trial data indicate that oral medications could match injectable drugs’ effectiveness and side effects. However, to mitigate side effects, they may require more frequent dosing or produce slightly less weight loss. Related: Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Pat

Goldman initiated coverage of Novo Nordisk A/S with a rating of Buy and set a new price target of $156.00

BMO Capital Markets initiated coverage of Novo Nordisk A/S with a rating of Outperform and set a new price target of $163.00

Morgan Stanley initiated coverage of Novo Nordisk A/S with a rating of Overweight and set a new price target of $120.00

UBS resumed coverage of Novo Nordisk A/S with a rating of Neutral

Cantor Fitzgerald initiated coverage of Novo Nordisk A/S with a rating of Overweight and set a new price target of $120.00

Argus initiated coverage of Novo Nordisk A/S with a rating of Buy and set a new price target of $110.00

HSBC Securities initiated coverage of Novo Nordisk A/S with a rating of Buy

Morgan Stanley upgraded Novo Nordisk A/S from Equal-Weight to Overweight

UBS downgraded Novo Nordisk A/S from Neutral to Sell

Exane BNP Paribas upgraded Novo Nordisk A/S from Underperform to Neutral

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced positive results demonstrating the anti-inflammatory potential of our anti-CD3 antibody (foralumab) in combination with semaglutide, a GLP-1 agonist marketed by Novo Nordisk (NYSE:NVO) under the brand names Ozempic and Wegovy. The data show that the combination of nasal anti-CD3 plus semaglutide improves liver homeostasis and reduces inflammation in models of diet-induced obesity (DIO

USA News Group News CommentaryIssued on behalf of PlantX Life Inc. VANCOUVER, BC, Oct. 24, 2024 /PRNewswire/ -- USA News Group News Commentary – With more than 100 million Americans struggling with obesity, and obesity rates increasing on every continent, it's no wonder why analysts at SNS Insider are projecting the Weight Loss Drugs Market to grow at a whopping 43.73% CAGR through 2032. It's one of the fastest growing markets in pharmaceuticals, with nearly one in four employers saying they're either somewhat or very likely to begin covering the cost of anti-obesity medications within the next year. Health and wellness companies are responding in kind, with recent market developments coming

NetworkNewsWire Editorial Coverage NEW YORK, Oct. 1, 2024 /PRNewswire/ -- Alzheimer's disease (AD) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S. Food and Drug Administration (FDA) approval. However, while these treatments may slow cognitive decline in AD patients, they do not actually improve cognition, a critical target for the millions suffering from the progressive disease. In addition, GLP-1 (glucagon-like peptide-1) drugs, which were originally developed to manage type 2 diabetes and since have seen significant effectiveness in treating obesity, have also shown potential in the treatment of Alzheimer's. However, th

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

Designed to celebrate diverse, unique portrayals of individuals who partner with their healthcare professional to change the course of their weight-management journey, while educating on the clinical data of Wegovy®Reflects the power of personal journeys to address stigma, and the importance of us all working together to address excess weight and treat obesityPLAINSBORO, N.J., June 3, 2024 /PRNewswire/ -- Novo Nordisk today launched The Power of Wegovy®, a new national campaign. The campaign aims to educate on the clinical data of Wegovy® (semaglutide) 2.4 mg injection and reflect the collective empowerment people living with obesity can feel when they don't have to manage their weight alone

Wegovy® (semaglutide) injection 2.4 mg is the first-and-only medicine indicated for both reduction of the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke and for long-term weight management1The approval is based on the results of SELECT, the largest cardiovascular outcomes trial ever completed for people with obesity and known heart disease2 PLAINSBORO, N.J., March 8, 2024 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy® to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with eithe

NetworkNewsWire Editorial Coverage NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer's, Parkinson's, and even drug addiction, plus there are strong indications of t

Novo Nordisk has been working to identify a sustainable approach to reduce insulin costs for patients that addresses changes in health policy and market shiftsLower list prices build on long-standing history of affordability initiatives already in place which can be accessed at NovoCare.comNovo Nordisk currently provides co-pay support for a number of insulin products meaning eligible patients can pay $25-35 for their insulin PLAINSBORO, N.J., March 14, 2023 /PRNewswire/ -- Novo Nordisk Inc. today announced it is lowering the U.S. list prices of several insulin products by up to 75% for people living with type 1 and type 2 diabetes. Products include both pre-filled pens and vials of basal (l

NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ:EXLS), a leading global data analytics and digital operations and solutions company, today announced that Andreas Fibig, a seasoned global executive with a strong record of innovation across industries and geographies, has been appointed to EXL's Board of Directors as an independent director effective Jan. 10, 2023. Fibig will be a member of the Board's Audit and Nominating and Governance Committees. "Andreas is a distinguished global business leader with more than 25 years of international health care, pharmaceutical, and consumer industry experience," said Vikram S. Pandit, Chairman of the Board of EXL. "We lo

Newly renovated medical centre designed to provide youth living with type 1 diabetes with on-site care HUNTSVILLE, ON, June 23, 2022 /CNW/ - Camp Huronda, home of Diabetes Canada's camp for children and youth living with type 1 diabetes and one of nine camps established under the D-Camps banner, is opening its doors to youth, families, and staff for the first time in two years. Diabetes Canada's Camps (D-Camps) strive to foster lifelong connections and provide exceptional programming for kids living with type 1 diabetes in a medically supervised environment. The old medical c